These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22183173)

  • 1. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Patel P; Wajima T; Peppercorn A; Piscitelli SC
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1627-9. PubMed ID: 22183173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.
    Song I; Borland J; Arya N; Wynne B; Piscitelli S
    J Clin Pharmacol; 2015 May; 55(5):490-6. PubMed ID: 25449994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
    Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of a paediatric granule formulation of the HIV integrase inhibitor dolutegravir in healthy adult subjects.
    Patel P; Song I; Borland J; Chen S; Peppercorn A; Wajima T; Funaki T; Fujita N; Hughes J; Piscitelli S
    Antivir Ther; 2014; 19(3):229-33. PubMed ID: 24275098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir.
    Song IH; Borland J; Chen S; Savina P; Peppercorn AF; Piscitelli S
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4394-7. PubMed ID: 23817375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
    Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
    Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.
    McMillan J; Szlachetka A; Slack L; Sillman B; Lamberty B; Morsey B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
    MacBrayne CE; Castillo-Mancilla J; Burton JR; MaWhinney S; Wagner CB; Micke K; Fey J; Huntley RT; Larson B; Bushman LR; Kiser JJ
    J Antimicrob Chemother; 2018 Jan; 73(1):156-159. PubMed ID: 29029135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.
    Castellino S; Moss L; Wagner D; Borland J; Song I; Chen S; Lou Y; Min SS; Goljer I; Culp A; Piscitelli SC; Savina PM
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3536-46. PubMed ID: 23669385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
    Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
    Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
    Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.
    Johnson M; Borland J; Chen S; Savina P; Wynne B; Piscitelli S
    Br J Clin Pharmacol; 2014 Nov; 78(5):1043-9. PubMed ID: 24838177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
    Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.